Ubs Group Ag Mirati Therapeutics, Inc. Transaction History

Ubs Group Ag

$400 Billion
Q2 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$41.99 - $62.38 $792,057 - $1.18 Million	18,863 Added 57.02%	51,945 $3.05 Million
Q3 2023 Nov 09, 2023	SELL	$27.8 - $45.35 $2.55 Million - $4.16 Million	-91,686 Reduced 73.49%	33,082 $1.44 Million
Q2 2023 Aug 11, 2023	BUY	$36.13 - $49.49 $1.57 Million - $2.14 Million	43,336 Added 53.22%	124,768 $4.51 Million
Q1 2023 May 12, 2023	SELL	$36.54 - $54.26 $2.13 Million - $3.16 Million	-58,300 Reduced 41.72%	81,432 $3.03 Million
Q4 2022 Feb 08, 2023	BUY	$41.27 - $98.62 $4.88 Million - $11.7 Million	118,286 Added 551.55%	139,732 $6.33 Million
Q3 2022 Nov 10, 2022	SELL	$59.5 - $86.7 $1.68 Million - $2.45 Million	-28,316 Reduced 56.9%	21,446 $1.5 Million
Q2 2022 Aug 10, 2022	BUY	$39.16 - $88.71 $1.63 Million - $3.7 Million	41,731 Added 519.62%	49,762 $3.34 Million
Q1 2022 May 16, 2022	SELL	$75.82 - $150.97 $2.4 Million - $4.77 Million	-31,607 Reduced 79.74%	8,031 $660,000
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $1.42 Million - $2.04 Million	10,732 Added 37.13%	39,638 $5.82 Million
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $3.15 Million - $4.23 Million	23,810 Added 467.23%	28,906 $5.11 Million
Q2 2021 Aug 13, 2021	SELL	$144.0 - $179.73 $710,784 - $887,147	-4,936 Reduced 49.2%	5,096 $823,000
Q1 2021 May 12, 2021	SELL	$158.92 - $221.61 $676,681 - $943,615	-4,258 Reduced 29.8%	10,032 $1.72 Million
Q4 2020 Feb 11, 2021	BUY	$162.05 - $240.27 $279,536 - $414,465	1,725 Added 13.73%	14,290 $3.14 Million
Q3 2020 Nov 12, 2020	SELL	$113.26 - $167.27 $1.38 Million - $2.03 Million	-12,148 Reduced 49.16%	12,565 $2.09 Million
Q2 2020 Jul 31, 2020	BUY	$72.01 - $120.39 $645,137 - $1.08 Million	8,959 Added 56.87%	24,713 $2.82 Million
Q1 2020 May 01, 2020	SELL	$69.78 - $116.21 $155,330 - $258,683	-2,226 Reduced 12.38%	15,754 $1.21 Million
Q4 2019 Feb 14, 2020	SELL	$70.76 - $128.86 $4.59 Million - $8.36 Million	-64,876 Reduced 78.3%	17,980 $2.32 Million
Q3 2019 Nov 14, 2019	BUY	$77.91 - $109.6 $4.86 Million - $6.83 Million	62,322 Added 303.51%	82,856 $6.46 Million
Q2 2019 Aug 14, 2019	BUY	$59.49 - $104.71 $1.04 Million - $1.83 Million	17,510 Added 579.03%	20,534 $2.12 Million
Q1 2019 May 14, 2019	SELL	$43.65 - $78.95 $7.5 Million - $13.6 Million	-171,857 Reduced 98.27%	3,024 $221,000
Q4 2018 Feb 14, 2019	BUY	$32.0 - $47.43 $4.67 Million - $6.92 Million	145,857 Added 502.54%	174,881 $7.42 Million
Q3 2018 Nov 14, 2018	BUY	$47.1 - $62.7 $1.25 Million - $1.66 Million	26,524 Added 1060.96%	29,024 $1.37 Million
Q2 2018 Aug 14, 2018	SELL	$26.05 - $52.4 $1.51 Million - $3.04 Million	-57,943 Reduced 95.86%	2,500 $123,000
Q1 2018 May 15, 2018	BUY	$17.2 - $34.95 $606,007 - $1.23 Million	35,233 Added 139.76%	60,443 $1.86 Million
Q4 2017 Feb 14, 2018	BUY	$12.65 - $19.0 $134,343 - $201,780	10,620 Added 72.79%	25,210 $460,000
Q3 2017 Nov 14, 2017	SELL	$4.7 - $11.7 $50,294 - $125,201	-10,701 Reduced 42.31%	14,590 $171,000
Q2 2017 Aug 14, 2017	BUY	N/A	2,796 Added 12.43%	25,291 $93,000
Q1 2017 Nov 14, 2017	BUY	N/A	22,495	22,495 $117,000

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account